Alexander F. Hau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexander F. Hau has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Drebka
Institute of Pharmaceutical Biology, Goethe-University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany
2 shared publications - Annika J. Scholl
Institute of Pharmaceutical Biology, Goethe-University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany
2 shared publications - Beatrice E. Bachmeier
Institute of Pharmaceutical Biology, Goethe-University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany
2 shared publications - Julie K. Könnecke
Institute of Pharmaceutical Biology, Goethe-University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany
2 shared publications - Nele L. Bößneck
Institute of Pharmaceutical Biology, Goethe-University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany
2 shared publications - Ralph Mösges
Universität zu Köln
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (11) , 220
Co-Medication and Anticholinergic Burden in Patients Using Ginkgo biloba Leaf Extract for Cognitive Impairment: Real-World Evidence from the PhytoVIS Database
Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. This retrospective cross-sectional study aimed to characterise concomitant medication use and explore its associations with GBE utilisation and patient-reported experiences using data from the pharmacoepidemiological database PhytoVIS. Methods: In a study cohort of 184 patients, we examined co-medication use, associations with GBE treatment habits (intake frequency, treatment duration, and daily dosage) and patient-reported perception of effectiveness and tolerability using descriptive statistics and exploratory non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients reporting adverse events (AEs) rated as significant, and patients with GABS scores >2. Results: Overall, 64.7% of patients used co-medication. Cardiovascular drugs were used by 27.7% of all patients, followed by antidiabetic drugs (11.4%) and analgesics/anti-inflammatory drugs (9.8%). While no statistically significant correlation with treatment duration was observed, our exploratory, unadjusted analysis indicated a weak negative correlation between the number of co-medications and daily GBE doses (Spearman’s ρ = −0.156, 95% CI [−0.299, −0.006], p = 0.037). Three patients reported AEs rated as significant during GBE intake. However, patients generally rated perceived effectiveness and tolerability favourably across co-medication groups. Four GBE users had calculated cumulative GABS scores >2 and rated the perceived effectiveness of GBE as moderate to very good without reporting any adverse events. Conclusion: Co-medication was common in GBE users, and patients rated the effectiveness and tolerability favourably across co-medication groups. The weak correlation between a higher number of co-medications and lower GBE doses should be interpreted cautiously as a hypothesis-generating finding. Overall, these findings highlight the relevance of considering concomitant medication when examining GBE utilisation, particularly in the context of self-medication.
- 18 November 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (11) , 220
Open AccessCo-Medication and Anticholinergic Burden in Patients Using Ginkgo biloba Leaf Extract for Cognitive Impairment: Real-World Evidence from the PhytoVIS Database
Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. This retrospective cross-sectional study aimed to characterise concomitant medication use and explore its associations with GBE utilisation and patient-reported experiences using data from the pharmacoepidemiological database PhytoVIS. Methods: In a study cohort of 184 patients, we examined co-medication use, associations with GBE treatment habits (intake frequency, treatment duration, and daily dosage) and patient-reported perception of effectiveness and tolerability using descriptive statistics and exploratory non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients reporting adverse events (AEs) rated as significant, and patients with GABS scores >2. Results: Overall, 64.7% of patients used co-medication. Cardiovascular drugs were used by 27.7% of all patients, followed by antidiabetic drugs (11.4%) and analgesics/anti-inflammatory drugs (9.8%). While no statistically significant correlation with treatment duration was observed, our exploratory, unadjusted analysis indicated a weak negative correlation between the number of co-medications and daily GBE doses (Spearman’s ρ = −0.156, 95% CI [−0.299, −0.006], p = 0.037). Three patients reported AEs rated as significant during GBE intake. However, patients generally rated perceived effectiveness and tolerability favourably across co-medication groups. Four GBE users had calculated cumulative GABS scores >2 and rated the perceived effectiveness of GBE as moderate to very good without reporting any adverse events. Conclusion: Co-medication was common in GBE users, and patients rated the effectiveness and tolerability favourably across co-medication groups. The weak correlation between a higher number of co-medications and lower GBE doses should be interpreted cautiously as a hypothesis-generating finding. Overall, these findings highlight the relevance of considering concomitant medication when examining GBE utilisation, particularly in the context of self-medication.
- Open Access
- 6 October 2026
- Published by MDPI AG in Preprints.org
Co-Medication and Anticholinergic Burden in Patients Using Ginkgo biloba Leaf Extract for Cognitive Impairment: Real-World Evidence from the PhytoVIS Database
Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. In this study, we investigated patient-reported outcomes from the pharmacoepidemiologic database PhytoVIS regarding GBE utilization for cognitive impairment in relation to co-medication. Methods: In a study cohort of 191 patients, we examined associations between co-medication and treatment patterns, perceived effectiveness and tolerability of GBE using descriptive statistics and non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients with significant adverse events (SAE) and patients with critical GABS scores. Results: Overall, 64.9% of patients used co-medication, most commonly cardiovascular drugs (47.5%), antidiabetic and analgesics/anti-inflammatory drugs (8.8% each). While there was no association with treatment duration or intake frequency, a higher number of co-medications was linked to lower GBE doses (p=0.03). Three patients reported SAEs during GBE intake, however overall perceived effectiveness and tolerability of GBE remained high irrespective of co-medication. Four GBE users had critical GABS scores (>2); all reported remission of cognitive symptoms. Conclusion: Although more co-medications were associated with lower GBE doses, perceived effectiveness and tolerability remained favourable. However, the findings highlight the importance of monitoring herbal medicinal products in self-medication, particularly in patients with co-medication, while also suggesting that GBE may support the management of cognitive impairment associated with anticholinergic therapies.
- 6 October 2026
- Published by MDPI AG in Preprints.org
Open AccessCo-Medication and Anticholinergic Burden in Patients Using Ginkgo biloba Leaf Extract for Cognitive Impairment: Real-World Evidence from the PhytoVIS Database
Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. In this study, we investigated patient-reported outcomes from the pharmacoepidemiologic database PhytoVIS regarding GBE utilization for cognitive impairment in relation to co-medication. Methods: In a study cohort of 191 patients, we examined associations between co-medication and treatment patterns, perceived effectiveness and tolerability of GBE using descriptive statistics and non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients with significant adverse events (SAE) and patients with critical GABS scores. Results: Overall, 64.9% of patients used co-medication, most commonly cardiovascular drugs (47.5%), antidiabetic and analgesics/anti-inflammatory drugs (8.8% each). While there was no association with treatment duration or intake frequency, a higher number of co-medications was linked to lower GBE doses (p=0.03). Three patients reported SAEs during GBE intake, however overall perceived effectiveness and tolerability of GBE remained high irrespective of co-medication. Four GBE users had critical GABS scores (>2); all reported remission of cognitive symptoms. Conclusion: Although more co-medications were associated with lower GBE doses, perceived effectiveness and tolerability remained favourable. However, the findings highlight the importance of monitoring herbal medicinal products in self-medication, particularly in patients with co-medication, while also suggesting that GBE may support the management of cognitive impairment associated with anticholinergic therapies.